Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the ‘Lab-in-the-Loop’ with NVIDIA
SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of novel therapeutics with AI-driven designs with NVIDIA technology....
Frost & Sullivan Identifies Top 50 Technologies Set to Shape a $1.25-$1.35 Trillion Market Opportunity by 2030
16th edition of annual Top 50 Technologies analysis highlights breakthrough innovations across healthcare, semiconductors, mobility, and clean energy LONDON, March 16, 2026 /PRNewswire/ -- Frost & Sullivan announces the release of the 16th edition of its annual Top 50 Technologies report, identifying the most transformative innovations poised to reshape industries and unlock new growth opportunities over the next five...
Laronix Launches Voice Restoration Study for ICU Patients at Greater Baltimore Medical Center
NEW YORK, March 16, 2026 /PRNewswire/ -- Laronix, Inc., a commercial-stage medical technology (MedTech) company and industry-leading innovator in voice restoration technologies, and the Greater Baltimore Medical Center (GBMC) announced the launch of an investigational study of Laronix MIRA Voice to restore voice capabilities for intensive care unit (ICU) patients. MIRA Voice...
Field Medical Names Mark A. Turco, MD, as Chief Executive Officer
CARDIFF-BY-THE-SEA, Calif., March 16, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing second-generation pulsed field ablation (PFA) solutions for complex ventricular and atrial arrhythmias, today announced the appointment of Mark A. Turco, MD, as chief executive officer, effective immediately. Dr. Mark A. Turco joins Field...
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alpha and IL-12/23 inhibitors providing a broader range of treatment solutions for immune-mediated...
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, particularly within the geriatric population. TAICHUNG, March 16, 2026 /PRNewswire/ -- Alar Pharmaceuticals...
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance Revenue: US$959.5 million, +61.4% year-on-year Gross profit: US$553.2 million, +103.3% year-on-year Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ProBio: US$388.7 million, +309.1% year-on-year Bestzyme: US$58.0 million, +7.9% year-on-year PISCATAWAY, N.J., March 16, 2026 /PRNewswire/...
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial results for the full year ended December 31, 2025, and provide a business update on March 26, 2026. The Company will hold...
InterSystems Honored with Four 2026 Best in KLAS Awards
Recognized for excellence in Acute Care EHR and Shared Care Records across Asia, Oceania, and Europe SINGAPORE, March 16, 2026 /PRNewswire/ -- InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1...
Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia
First insurer in Asia to bring the innovative blood-based multi‑cancer screening solution to Hong Kong, Singapore, and the Philippines TSX/NYSE/PSE: MFC SEHK: 945 HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ -- Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, becoming...
